Madrigal Pharmaceuticals Off Highs, Remains Up 13% in Afternoon Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy MDGL?
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 529.840
Low
527.00
Averages
636.22
High
900.00
Current: 529.840
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating significant growth potential that attracts investor interest.
- Manufacturing Challenge Solution: Avaí Bio has initiated the manufacturing of a Master Cell Bank for genetically modified cells overexpressing α-Klotho in collaboration with Austrianova, aiming to address the production bottlenecks in cell therapy and lay the groundwork for future commercialization.
- Innovative Delivery Mechanism: Austrianova's Cell-in-a-Box® technology protects therapeutic cells within a biocompatible shell, allowing continuous secretion of α-Klotho, which eliminates the manufacturing and logistical burdens of patient-specific autologous therapies, transforming it into a scalable product.
- Dual-Program Strategy: Avaí Bio's dual-program approach targets both the Klothonova α-Klotho anti-aging platform and the Insulinova diabetes program, expected to tap into multi-billion dollar markets, showcasing the company's strategic positioning in the regenerative medicine sector.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Manufacturing Challenges: The primary bottleneck for cell therapy companies is how to manufacture living therapeutics reliably and affordably at scale, and those who solve this issue will dominate the market.
- Innovative Technology: Avaí Bio has initiated the manufacturing of a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein in collaboration with Austrianova, utilizing Cell-in-a-Box® technology to ensure continuous secretion of the protein without immune rejection.
- Broad Market Demand: α-Klotho is linked to various diseases such as Alzheimer's, cardiovascular disease, and kidney disease, presenting significant market opportunities, and Avaí Bio's dual-program approach aims to effectively address treatment needs in these areas.
See More
MDGL Stock Rises Significantly in a Month Amid Eli Lilly Acquisition Rumors
Madrigal's Focus: Madrigal is concentrating on developing therapies for metabolic dysfunction associated with MASH, with its Rezdiffran drug already approved by the U.S. FDA for treating moderate to advanced fibrosis.
Financial Performance: The company reported Rezdiffran sales of $958.4 million for the full year 2025, with over 36,250 patients on the drug by the end of that year.
Expansion Plans: Madrigal has licensed global rights to six pre-clinical siRNA programs for up to $4.4 billion to expand its pipeline and is evaluating the drug for treating compensated MASH cirrhosis.
Market Reaction: Following speculation about a potential buyout by Eli Lilly, Madrigal's stock saw a significant increase, with retail sentiment shifting from neutral to extremely bullish.
See More
Wall Street Declines Amid Rising U.S.-Iran Tensions
- Market Decline: Wall Street ended lower on Thursday as investors monitored escalating U.S.-Iran tensions, with the Nasdaq Composite down 2.3%, the S&P 500 down 1.7%, and the Dow Jones Industrial Average down 1%, indicating market sensitivity to geopolitical risks.
- Madrigal Stock Surge: Madrigal Pharmaceuticals saw a 12% increase in stock price amid renewed speculation of a potential takeover, as traders cited a Betaville report indicating the company has hired advisers for talks with a buyer, reflecting optimistic market sentiment regarding its future.
- Macy's Mixed Results: Despite reporting positive early results from its Google Gemini-powered chatbot, Macy's stock dipped 0.5%, with data showing customers using the “Ask Macy’s” assistant spent approximately 4.75 times more than those who did not, suggesting cautious market sentiment about its long-term growth potential.
- Modular Medical Stock Split: Modular Medical announced a 1-for-30 reverse stock split effective March 31, 2026, aimed at raising its share price to meet Nasdaq's $1 minimum bid requirement, reducing outstanding shares from approximately 139.8 million to about 4.66 million, highlighting the company's commitment to maintaining its listing status.
See More
Madrigal Pharmaceuticals Shares Surge 12% Amid Takeover Speculation
- Takeover Speculation: Madrigal Pharmaceuticals (MDGL) shares rose 12% amid renewed speculation of a potential acquisition, reflecting investor optimism about the company's future prospects.
- Market Capitalization: With a market cap of $12 billion, Madrigal demonstrates a strong position in the biopharmaceutical sector, attracting interest from potential buyers.
- Short Interest Ratio: Madrigal's short interest stands at 16%, indicating market expectations for stock price volatility, which may influence future investment decisions.
- Future Growth Potential: Madrigal anticipates robust net sales growth in 2026 and an expanding pipeline, coupled with a 50% surge in the MASH market, further enhancing its attractiveness.
See More
U.S. Markets Declined on Thursday; Karman Holdings Experienced Largest Loss
- Stock Market Decline: U.S. stock indexes experienced a decline on Thursday, with significant drops across major indices.
- Index Performance: The S&P 500 fell by 2.38%, the Dow Jones dropped 1.74%, and the Nasdaq decreased by 1.01%.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating significant growth potential that attracts investor interest.
- Manufacturing Challenge Solution: Avaí Bio has initiated the manufacturing of a Master Cell Bank for genetically modified cells overexpressing α-Klotho in collaboration with Austrianova, aiming to address the production bottlenecks in cell therapy and lay the groundwork for future commercialization.
- Innovative Delivery Mechanism: Austrianova's Cell-in-a-Box® technology protects therapeutic cells within a biocompatible shell, allowing continuous secretion of α-Klotho, which eliminates the manufacturing and logistical burdens of patient-specific autologous therapies, transforming it into a scalable product.
- Dual-Program Strategy: Avaí Bio's dual-program approach targets both the Klothonova α-Klotho anti-aging platform and the Insulinova diabetes program, expected to tap into multi-billion dollar markets, showcasing the company's strategic positioning in the regenerative medicine sector.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Manufacturing Challenges: The primary bottleneck for cell therapy companies is how to manufacture living therapeutics reliably and affordably at scale, and those who solve this issue will dominate the market.
- Innovative Technology: Avaí Bio has initiated the manufacturing of a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein in collaboration with Austrianova, utilizing Cell-in-a-Box® technology to ensure continuous secretion of the protein without immune rejection.
- Broad Market Demand: α-Klotho is linked to various diseases such as Alzheimer's, cardiovascular disease, and kidney disease, presenting significant market opportunities, and Avaí Bio's dual-program approach aims to effectively address treatment needs in these areas.
See More
MDGL Stock Rises Significantly in a Month Amid Eli Lilly Acquisition Rumors
Madrigal's Focus: Madrigal is concentrating on developing therapies for metabolic dysfunction associated with MASH, with its Rezdiffran drug already approved by the U.S. FDA for treating moderate to advanced fibrosis.
Financial Performance: The company reported Rezdiffran sales of $958.4 million for the full year 2025, with over 36,250 patients on the drug by the end of that year.
Expansion Plans: Madrigal has licensed global rights to six pre-clinical siRNA programs for up to $4.4 billion to expand its pipeline and is evaluating the drug for treating compensated MASH cirrhosis.
Market Reaction: Following speculation about a potential buyout by Eli Lilly, Madrigal's stock saw a significant increase, with retail sentiment shifting from neutral to extremely bullish.
See More
Wall Street Declines Amid Rising U.S.-Iran Tensions
- Market Decline: Wall Street ended lower on Thursday as investors monitored escalating U.S.-Iran tensions, with the Nasdaq Composite down 2.3%, the S&P 500 down 1.7%, and the Dow Jones Industrial Average down 1%, indicating market sensitivity to geopolitical risks.
- Madrigal Stock Surge: Madrigal Pharmaceuticals saw a 12% increase in stock price amid renewed speculation of a potential takeover, as traders cited a Betaville report indicating the company has hired advisers for talks with a buyer, reflecting optimistic market sentiment regarding its future.
- Macy's Mixed Results: Despite reporting positive early results from its Google Gemini-powered chatbot, Macy's stock dipped 0.5%, with data showing customers using the “Ask Macy’s” assistant spent approximately 4.75 times more than those who did not, suggesting cautious market sentiment about its long-term growth potential.
- Modular Medical Stock Split: Modular Medical announced a 1-for-30 reverse stock split effective March 31, 2026, aimed at raising its share price to meet Nasdaq's $1 minimum bid requirement, reducing outstanding shares from approximately 139.8 million to about 4.66 million, highlighting the company's commitment to maintaining its listing status.
See More
Madrigal Pharmaceuticals Shares Surge 12% Amid Takeover Speculation
- Takeover Speculation: Madrigal Pharmaceuticals (MDGL) shares rose 12% amid renewed speculation of a potential acquisition, reflecting investor optimism about the company's future prospects.
- Market Capitalization: With a market cap of $12 billion, Madrigal demonstrates a strong position in the biopharmaceutical sector, attracting interest from potential buyers.
- Short Interest Ratio: Madrigal's short interest stands at 16%, indicating market expectations for stock price volatility, which may influence future investment decisions.
- Future Growth Potential: Madrigal anticipates robust net sales growth in 2026 and an expanding pipeline, coupled with a 50% surge in the MASH market, further enhancing its attractiveness.
See More
U.S. Markets Declined on Thursday; Karman Holdings Experienced Largest Loss
- Stock Market Decline: U.S. stock indexes experienced a decline on Thursday, with significant drops across major indices.
- Index Performance: The S&P 500 fell by 2.38%, the Dow Jones dropped 1.74%, and the Nasdaq decreased by 1.01%.
See More
